ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0789

Telomere Length of Peripheral Blood Cells Predicts More Severe Pulmonary Disease and Worse Survival in Systemic Sclerosis
Abstract Number: 0790

Transcriptomic Analyses of Lung Tissues Reveals Potential Key Genes Associated with Progression of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD)
Abstract Number: 0791

Expression of TL1A, Inflammatory, and Fibrotic Pathways in Patients with Diffuse Systemic Sclerosis
Abstract Number: 0792

Single Cell RNA-seq of Myeloid Cells from Systemic Sclerosis Patients Identifies Circulating Monocyte Population with Interferon Signature Associated with Interstitial Lung Disease
Abstract Number: 0793

The Dual Specificity Phosphatase 6 (DUSP6) Regulates Arthritis Severity and IL10 Production
Abstract Number: 0794

Microbiota-dependent Indole Production Is Required for the Development of Collagen-induced Arthritis
Abstract Number: 0795

The Focal Adhesion Protein Lasp1 Links the Arp2/3 Complex to Cell-to-cell Contact Formation in Arthritic Fibroblast-like Synoviocytes
Abstract Number: 0796

Role of Group 2 Innate Lymphoid Cells in the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 0797

Innate Lymphoid Cells Enhance Development of CD4+ T-cell Driven Autoimmune Arthritis
Abstract Number: 0798

A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages
Abstract Number: 0799

Human Chimeric Antigen Receptor (CAR)-Tregs Targeting OX40L for Treatment of Systemic Lupus Erythematosus
Abstract Number: 0800

CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis
Abstract Number: 0801

LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease
Abstract Number: 0802

Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells
Abstract Number: 0803

IL10 Inhibits Toll-like Receptor-9-induced T Cell Receptor-mediated T Cell Activation in Macrophage Activation Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].